What role does lamotrigine (Lamictal) have in treating obsessive‑compulsive disorder (OCD) for a patient who reports feeling a boost?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Lamotrigine as Augmentation in Treatment-Resistant OCD

Lamotrigine (Lamictal) has an emerging role as a glutamatergic augmentation agent for SSRI-resistant OCD, and your patient's reported "boost" aligns with evidence showing it can improve both obsessive-compulsive symptoms and mood in treatment-refractory cases.

Evidence-Based Role in OCD Treatment

Position in Treatment Algorithm

Lamotrigine is not a first-line treatment for OCD but serves as an augmentation strategy for patients who fail to respond adequately to SSRIs 1. According to the 2019 Nature Reviews Disease Primers guidelines, glutamatergic medications including lamotrigine are considered after:

  • Adequate SSRI trials (8-12 weeks at maximum tolerated doses)
  • SSRI switching attempts
  • Consideration of CBT augmentation (if available)

Evidence for Efficacy

The evidence base for lamotrigine in OCD is moderate but positive:

  • Two randomized controlled trials demonstrate efficacy 1
  • A 2016 Iranian RCT (n=53) showed lamotrigine 100mg augmentation produced significant reductions in Y-BOCS scores: obsessions (p=0.01), compulsions (p=0.005), and total scores (p=0.007) with an effect size of 0.54 2
  • A 2012 double-blind RCT (n=33) over 16 weeks demonstrated highly significant improvements in obsessions (p<0.0001), compulsions (p<0.0001), and notably also improved depressive symptoms (p<0.0001) 3
  • A 2015 retrospective review (n=22) showed 20/22 patients responded with mean Y-BOCS reduction of 67.23% at mean dose of 150mg/day 4

Why Your Patient May Feel a "Boost"

The "boost" your patient describes likely reflects lamotrigine's dual action on both OCD symptoms and mood:

  1. Mood enhancement: Lamotrigine significantly improves comorbid depressive symptoms in OCD patients, which may manifest as increased energy and motivation 3
  2. Glutamatergic modulation: By modulating glutamate neurotransmission in cortico-striato-thalamo-cortical circuits implicated in OCD, it may reduce the cognitive burden of obsessions 1
  3. Rapid onset: Some patients show early improvement, though full effects typically emerge over 8-16 weeks 2, 3

Clinical Recommendations

Dosing Strategy

Based on the evidence:

  • Target dose: 100-150mg/day 2, 3, 4
  • Titrate slowly per standard lamotrigine protocols to minimize rash risk
  • Full assessment of response at 12-16 weeks

When to Consider Lamotrigine

Prioritize lamotrigine augmentation when:

  • Patient has failed adequate SSRI trial(s)
  • Comorbid depression is present (dual benefit) 3
  • Patient prefers to avoid antipsychotics (which have metabolic risks) 1
  • N-acetylcysteine or memantine are unavailable or not tolerated

The 2019 guidelines note that among glutamatergic agents, N-acetylcysteine has the largest evidence base (3/5 positive RCTs), followed by memantine, then lamotrigine 1. However, a 2023 systematic review specifically recommends lamotrigine as one of the three most supported augmentation agents alongside memantine and aripiprazole 5.

Critical Safety Considerations

From the FDA label, you must monitor for 6:

  1. Serious rash/DRESS syndrome: Occurs in early treatment; requires immediate discontinuation if suspected
  2. Cardiac conduction abnormalities: Lamotrigine exhibits Class IB antiarrhythmic activity and can prolong QRS in patients with structural heart disease—assess cardiac history before initiating
  3. Blood dyscrasias: Monitor for neutropenia, leukopenia, thrombocytopenia
  4. Suicidal ideation: Standard AED monitoring applies

Comparison to Alternatives

If lamotrigine is insufficient or not tolerated:

  • Antipsychotics (aripiprazole, risperidone): More evidence but significant metabolic side effects; only 1/3 of SSRI-resistant patients respond 1
  • N-acetylcysteine: Largest glutamatergic evidence base 1
  • Memantine: Multiple positive trials 1

Clinical Pitfalls to Avoid

  1. Don't use lamotrigine as monotherapy—it's an augmentation agent only
  2. Don't rush the titration—rash risk is dose-dependent and titration-speed dependent
  3. Don't stop SSRIs when adding lamotrigine—maintain the base SSRI therapy
  4. Don't assess response before 8-12 weeks—though some patients improve earlier, full effects take time 2, 3
  5. Screen for bipolar disorder—while lamotrigine is mood-stabilizing, unrecognized bipolar disorder changes the treatment paradigm entirely

Bottom Line for Your Patient

Your patient's subjective "boost" is consistent with lamotrigine's documented effects on both OCD symptoms and mood. Continue the current regimen, monitor for the serious but rare adverse effects noted above, and formally reassess OCD symptom severity at 12-16 weeks using Y-BOCS scoring. The evidence supports this as a rational, evidence-based augmentation strategy for SSRI-resistant OCD, particularly given the apparent mood benefit your patient is experiencing 2, 3, 4, 5.

References

1
Guideline

obsessive-compulsive disorder.

Nature Reviews Disease Primers, 2019

Related Questions

Is lamotrigine an appropriate treatment option for obsessive‑compulsive disorder in adults who have failed an adequate trial of an SSRI, and what is the recommended dosing schedule and monitoring?
Has lamotrigine (Lamictal) been tried as an augmentation for obsessive‑compulsive disorder?
Is lamotrigine appropriate as augmentation for persistent intrusive thoughts after an adequate SSRI trial and exposure‑and‑response‑prevention therapy, and what dosing schedule and safety monitoring are recommended?
Is lamotrigine (Lamictal) appropriate for treating Obsessive-Compulsive Disorder (OCD)?
Can the combination of lamotrigine and olanzapine be effective for treating obsessive‑compulsive disorder after first‑line therapies have failed?
Why do patients with myasthenia gravis develop cough and dysphagia?
Why are side effects increased when sertraline is not taken daily?
In a patient who has had several falls in the last few weeks, which selective serotonin reuptake inhibitor (SSRI) has the lowest fall‑risk profile?
What are the indications, pre‑operative workup, surgical options, and postoperative management for mastectomy in invasive breast cancer?
What antidepressant should this patient be switched to from paroxetine (Paxil) to reduce fall risk?
What is the justification for using an outpatient level of care with bi‑weekly medication management (initially) and weekly cognitive‑behavioral therapy for a 12‑week acute phase in a patient with moderate major depressive disorder?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.